New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 9, 2014
07:09 EDTBIIB, SGMOBiogen and Sangamo collaborate for hemoglobinopathy treatment development
Biogen (BIIB) and Sangamo (SGMO) announced an exclusive worldwide collaboration and license agreement focused on the development of therapeutics for hemoglobinopathies, inherited conditions that result from the abnormal structure or underproduction of hemoglobin. Sangamo is responsible for all research and development activities, and both companies will perform activities to enable submission of an Investigational New Drug Application for SCD. Biogen will provide Sangamo with an upfront payment of $20M and will reimburse Sangamo for its internal and external research and development program-related costs. Sangamo may also receive additional payments of approximately $300M based on the achievement of certain milestones, as well as double digit royalties on product sales.
News For BIIB;SGMO From The Last 14 Days
Check below for free stories on BIIB;SGMO the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
July 21, 2014
07:37 EDTBIIBBiogen July weekly volatility elevated into Q2 and outlook
Biogen July weekly call option implied volatility is at 55, August is at 34, October is at 36; compared to its 26-week average of 33 according to Track Data, suggesting large near term price movement into the expected release of Q2 on July 23.
July 9, 2014
07:23 EDTBIIBBiogen price target raised to $375 from $325 at RBC Capital
Subscribe for More Information
July 8, 2014
07:31 EDTSGMOPiper Jaffray to hold a symposium
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use